H35.3 H34.8
Conditions
Interventions
Group 1: Treatment of patients with AMD, DME, or RVO, with anti-VEGF agents (Avastin, Lucentis, Eylea), according to the official guidelines by DOG (Deutsche Ophthalmologische Gesellschaft), RG (Retin
Sponsors
Universitäts-Augenklinik Freiburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients receiving intravitreal injections of anti-VEGF for AMD, DME, or RVO patients who were monitored in our IVOM-outpatients clinic and who received their first injection at least 12 months ago informed consent
Exclusion criteria
Exclusion criteria: VA-limiting ocular comorbidity (such as other maculopathies, advanced or uncontrolled glaucoma). Vitrectomy in patient history in study eye. VA-relevant surgery during study (such as cataract surgery).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of patients with loss of <15 letters visual acuity after 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| change of visual acuity (VA) within 12/24/36 months proportion of patients with a) loss of <15 letters after 24/36 months b) gain of at least 15 letters after 12/24/36 months descriptive statistics: number of injections within up to 36 months rate of injections-free intervals of at least 6/8/12 weeks proportion of patients with active disease or under regular control examinations after 12/24/36 months test for differences between the aforementioned indications (AMD; DME; RVO) | — |
Countries
Germany
Contacts
Public ContactChristoph Ehlken
Universitäts-Augenklinik Freiburg
Outcome results
None listed